Search the GHTC website

Global health R&D delivers for New Jersey

US government investment in global health R&D has delivered

$1.5 billlion
to New Jersey research institutions
18,700+ new jobs
for New Jersey
New Jersey's top USG-funded global health R&D institutions

New Jersey's top USG-funded global health R&D institutions

Johnson & Johnson
$726.2 million
Undisclosed NJ-based industry recipients
$274.9 million
Rutgers, The State University of New Jersey (including Rutgers Biomedical and Health Sciences and the Robert Wood Johnson Medical School)
$178.5 million
MSD (also known as Merck & Co.)
$171 million
University of Medicine and Dentistry of New Jersey (formely independent, now part of Rutgers)*
$76 million
Hackensack University Medical Center
$35.2 million
Princeton University
$16.3 million
Becton, Dickinson and Company (BD)
$15.6 million
Vaxinnate Corporation*
$4.5 million
Analytical Diagnostic Solutions Inc.
$3.9 million
Prokaryotics Inc.
$3.3 million
Allied Innovative Systems LLC
$2.9 million
Celldex Therapeutics
$2.8 million
Advanced Biodevices LLC*
$2.1 million
Soligenix Inc.
$1.5 million
PTC Therapeutics
$1.4 million
US Public Health Research Institute (formerly independent, now part of Rutgers)*
$1.3 million
$800 thousand
Theradex Systems
$740 thousand
New Jersey Institute of Technology
$519 thousand
Drew University
$473 thousand
B&W Tek
$343 thousand
Menssana Research Inc.
$286 thousand
Nostrum Technologies
$283 thousand
Aucta Pharmaceuticals
$282 thousand
Matinas BioPharma (including Aquarius Biotechnologies)
$278 thousand
PharmaSeq Inc.*
$169 thousand

New Jersey's top areas of global health R&D by USG funding

Flioviral diseases (including Ebola, Marburg)
Bacterial pneumonia & meningitis
Cryptococcal meningitis
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Helminth infections (worms & flukes)
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Salmonella infections
Global health R&D at work in New Jersey

Rutgers New Jersey Medical School helped develop a new rapid test for tuberculosis (TB). The test, Xpert® MTB/RIF Ultra, is a second-generation version of a test that revolutionized TB diagnosis. Like its predecessor, Ultra is fast, accurate, easy to use, and needs no extra equipment—making it particularly suitable for low-resource settings. But Ultra is better able to detect TB in children, people with HIV, and certain drug-resistant cases. Results from Ultra allow patients to start on treatment quickly and receive the appropriate therapy if their strain is drug resistant, increasing treatment success rates and reducing the spread of the world’s second deadliest infectious disease killer following COVID-19.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: © 2013 Michael Tran/Interactive Research and Development, Courtesy of Photoshare